Danaher (NYSE:DHR) Given New $315.00 Price Target at TD Cowen

Danaher (NYSE:DHR) had its price target hoisted by TD Cowen from $310.00 to $315.00 in a research report sent to investors on Wednesday, Benzinga reports. The firm currently has a buy rating on the conglomerate’s stock.

Other research analysts have also recently issued research reports about the stock. Bank of America raised their price target on shares of Danaher from $270.00 to $275.00 and gave the stock a “neutral” rating in a report on Wednesday, July 24th. Royal Bank of Canada lowered their price target on Danaher from $333.00 to $311.00 and set an “outperform” rating for the company in a research report on Wednesday. Leerink Partners increased their price objective on Danaher from $275.00 to $280.00 and gave the company an “outperform” rating in a report on Wednesday, July 24th. The Goldman Sachs Group raised their price objective on Danaher from $225.00 to $250.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 24th. Finally, Barclays cut their price target on shares of Danaher from $285.00 to $275.00 and set an “equal weight” rating on the stock in a report on Wednesday. Seven analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $287.28.

Danaher Price Performance

NYSE DHR opened at $256.00 on Wednesday. Danaher has a 12-month low of $182.09 and a 12-month high of $281.70. The firm’s fifty day simple moving average is $270.43 and its two-hundred day simple moving average is $260.43. The company has a current ratio of 1.43, a quick ratio of 1.04 and a debt-to-equity ratio of 0.33. The firm has a market capitalization of $189.62 billion, a P/E ratio of 43.39, a P/E/G ratio of 4.49 and a beta of 0.83.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, topping the consensus estimate of $1.57 by $0.14. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The business had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.59 billion. During the same quarter last year, the company earned $2.02 earnings per share. The company’s quarterly revenue was up 3.1% on a year-over-year basis. Analysts forecast that Danaher will post 7.59 EPS for the current fiscal year.

Danaher Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, October 25th. Investors of record on Friday, September 27th will be issued a $0.27 dividend. This represents a $1.08 annualized dividend and a yield of 0.42%. The ex-dividend date of this dividend is Friday, September 27th. Danaher’s payout ratio is presently 18.31%.

Insider Buying and Selling at Danaher

In other news, SVP Georgeann Couchara sold 952 shares of the business’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $268.37, for a total transaction of $255,488.24. Following the completion of the sale, the senior vice president now owns 4,212 shares of the company’s stock, valued at $1,130,374.44. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other news, SVP Georgeann Couchara sold 952 shares of Danaher stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $268.37, for a total value of $255,488.24. Following the sale, the senior vice president now directly owns 4,212 shares of the company’s stock, valued at $1,130,374.44. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Rainer Blair sold 9,007 shares of the business’s stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total value of $2,521,960.00. Following the sale, the chief executive officer now owns 97,983 shares of the company’s stock, valued at $27,435,240. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 30,059 shares of company stock valued at $8,400,897 over the last ninety days. Corporate insiders own 11.10% of the company’s stock.

Hedge Funds Weigh In On Danaher

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. boosted its holdings in shares of Danaher by 7.4% during the 1st quarter. Vanguard Group Inc. now owns 60,107,030 shares of the conglomerate’s stock worth $15,009,928,000 after purchasing an additional 4,163,657 shares during the last quarter. Swedbank AB acquired a new position in Danaher during the first quarter worth $676,545,000. TD Asset Management Inc grew its holdings in Danaher by 99.0% in the 2nd quarter. TD Asset Management Inc now owns 1,358,706 shares of the conglomerate’s stock valued at $339,473,000 after buying an additional 675,952 shares in the last quarter. Massachusetts Financial Services Co. MA increased its stake in shares of Danaher by 22.7% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 3,047,728 shares of the conglomerate’s stock worth $761,475,000 after acquiring an additional 563,546 shares during the last quarter. Finally, International Assets Investment Management LLC increased its stake in shares of Danaher by 40,196.5% in the 3rd quarter. International Assets Investment Management LLC now owns 429,964 shares of the conglomerate’s stock worth $119,539,000 after acquiring an additional 428,897 shares during the last quarter. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.